These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 1981370)

  • 21. [Reevaluation of current antimicrobials. Cefpodoxime proxetil. Discussion].
    Jpn J Antibiot; 1995 Feb; 48(2):183-90. PubMed ID: 7745807
    [No Abstract]   [Full Text] [Related]  

  • 22. Activity of cefpodoxime, an oral 3rd generation cephalosporin.
    Raymond N; Lang S
    N Z Med J; 1993 Feb; 106(949):44. PubMed ID: 8464593
    [No Abstract]   [Full Text] [Related]  

  • 23. Investigation of factors responsible for low oral bioavailability of cefpodoxime proxetil.
    Kakumanu VK; Arora V; Bansal AK
    Int J Pharm; 2006 Jul; 317(2):155-60. PubMed ID: 16621365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [RU 51807 (cefpodoxime proxetil). In vitro and in vivo antibacterial activity of a new orally administered active cephalosporin].
    Chantot JF; Mauvais P
    Pathol Biol (Paris); 1991 Jan; 39(1):17-27. PubMed ID: 1901403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cefpodoxime proxetil--a new oral cephalosporin.
    Med Lett Drugs Ther; 1992 Nov; 34(884):107-8. PubMed ID: 1435506
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical evaluation of cefpodoxime proxetil dry syrup in pediatric cutaneous bacterial infection.
    Terui T; Tagami H
    J Chemother; 1995 Nov; 7 Suppl 4():119-21. PubMed ID: 8904129
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison of cefpodoxime proxetil and cefixime in the treatment of acute otitis media in infants and children. Otitis Study Group.
    Asmar BI; Dajani AS; Del Beccaro MA; Mendelman PM
    Pediatrics; 1994 Dec; 94(6 Pt 1):847-52. PubMed ID: 7971000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical evaluation of cefpodoxime proxetil in patients with dermatological infections.
    Imaizumi T; Ishikawa H; Hashimoto I
    J Chemother; 1995 Nov; 7 Suppl 4():137-41. PubMed ID: 8904135
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacokinetic study and clinical evaluation of cefpodoxime proxetil in the elderly with impaired renal function.
    Ishioka T
    J Chemother; 1995 Nov; 7 Suppl 4():122-3. PubMed ID: 8904130
    [No Abstract]   [Full Text] [Related]  

  • 30. [Cefpodoxime, the new oral 3rd generation cephalosporin. Symposium of the 17th International Chemotherapy Congress (ICC). Berlin, 26 June 1991].
    Fortschr Med Suppl; 1991; 114():1-15. PubMed ID: 1682227
    [No Abstract]   [Full Text] [Related]  

  • 31. An improved method for preparation of cefpodoxime proxetil.
    Rodríguez JC; Hernández R; González M; Rodríguez Z; Tolón B; Velez H; Valdés B; López MA; Fini A
    Farmaco; 2003 May; 58(5):363-9. PubMed ID: 12729830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cefpodoxime proxetil for infective exacerbations of chronic obstructive airway disease.
    Alderman CP
    Ann Pharmacother; 1996 Feb; 30(2):196. PubMed ID: 8835062
    [No Abstract]   [Full Text] [Related]  

  • 33. Isolation and characterization of side-products formed through ∆2-isomerization in the synthesis of cefpodoxime proxetil.
    Pieper M; Schleich H; Gröger H
    J Antibiot (Tokyo); 2019 Sep; 72(9):702-708. PubMed ID: 31217553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microbiological and clinical studies on cefpodoxime proxetil for bacterial skin and soft tissue infections in pediatric patients.
    Ito K; Ito M
    J Chemother; 1995 Nov; 7 Suppl 4():124-6. PubMed ID: 8904131
    [No Abstract]   [Full Text] [Related]  

  • 35. [Respiratory tract infections in general practice. Cefpodoxime proxetil in patients with risk factors and concomitant illnesses].
    Kardos P; Wiese K
    MMW Fortschr Med; 2000 Feb; 142(5):41. PubMed ID: 10715939
    [No Abstract]   [Full Text] [Related]  

  • 36. Simultaneous spectrophotometric determination of Cefpodoxime proxetil and Potassium clavulanate.
    Gandhi SV; Patil UP; Patil NG
    Hindustan Antibiot Bull; 2009; 51(1-4):24-8. PubMed ID: 21268556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of cefpodoxime proxetil dry syrup in pediatric patients with various infections.
    Muranaka H; Yokoyama M
    J Chemother; 1995 Nov; 7 Suppl 4():127-30. PubMed ID: 8904132
    [No Abstract]   [Full Text] [Related]  

  • 38. A multi-institutional study on clinical effectiveness of cefpodoxime proxetil dry syrup in childhood infections.
    Imanaka H; Kitahara T; Yoshinaga M; Miyata K
    J Chemother; 1995 Nov; 7 Suppl 4():131-3. PubMed ID: 8904133
    [No Abstract]   [Full Text] [Related]  

  • 39. Gastric emptying and the pharmacokinetics of the cephalosporin antibiotic, cefpodoxime proxetil.
    Hughes GS; Heald DL; Patel R; Spillers CR; Batts DH; Euler AR
    Methods Find Exp Clin Pharmacol; 1990 Apr; 12(3):197-204. PubMed ID: 2352449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost saving of 5-day therapy with cefpodoxime proxetil versus standard 10-day beta-lactam therapy for recurrent pharyngotonsillitis in adults. A prospective general practice study.
    Pelc A; Portier H; Gehanno P; Fiessinger S; Ichou F
    Pharmacoeconomics; 1996 Sep; 10(3):239-50. PubMed ID: 10172792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.